300642 Stock Overview
Researches and develops, manufactures, and distributes IVDs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Tellgen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.69 |
| 52 Week High | CN¥19.28 |
| 52 Week Low | CN¥9.94 |
| Beta | 0.42 |
| 11 Month Change | 5.59% |
| 3 Month Change | 30.42% |
| 1 Year Change | -17.55% |
| 33 Year Change | -48.86% |
| 5 Year Change | -30.51% |
| Change since IPO | -18.50% |
Recent News & Updates
Shareholder Returns
| 300642 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -5.4% | -0.4% | -0.9% |
| 1Y | -17.6% | -7.3% | 5.4% |
Return vs Industry: 300642 underperformed the CN Medical Equipment industry which returned -7.3% over the past year.
Return vs Market: 300642 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
| 300642 volatility | |
|---|---|
| 300642 Average Weekly Movement | 10.9% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300642's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300642's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 574 | Jian Er Yao | www.tellgen.com |
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; cardiovascular and inflammation; biochemistry kits; DNA methylation testing kits; and molecular detection of COVID-19 and others. It also provides diagnostic reagents/testing instruments and assembly lines.
Tellgen Corporation Fundamentals Summary
| 300642 fundamental statistics | |
|---|---|
| Market cap | CN¥2.53b |
| Earnings (TTM) | CN¥70.88m |
| Revenue (TTM) | CN¥462.55m |
35.7x
P/E Ratio5.5x
P/S RatioIs 300642 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300642 income statement (TTM) | |
|---|---|
| Revenue | CN¥462.55m |
| Cost of Revenue | CN¥160.67m |
| Gross Profit | CN¥301.87m |
| Other Expenses | CN¥230.99m |
| Earnings | CN¥70.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 65.26% |
| Net Profit Margin | 15.32% |
| Debt/Equity Ratio | 5.0% |
How did 300642 perform over the long term?
See historical performance and comparison